Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H5NO3 |
| Molecular Weight | 151.1195 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC2=C(N1)C=CO2
InChI
InChIKey=MMAIBGHDBYQYDI-UHFFFAOYSA-N
InChI=1S/C7H5NO3/c9-7(10)5-3-6-4(8-5)1-2-11-6/h1-3,8H,(H,9,10)
| Molecular Formula | C7H5NO3 |
| Molecular Weight | 151.1195 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:40:48 GMT 2023
by
admin
on
Sat Dec 16 11:40:48 GMT 2023
|
| Record UNII |
NPA5DYB93P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60427996
Created by
admin on Sat Dec 16 11:40:48 GMT 2023 , Edited by admin on Sat Dec 16 11:40:48 GMT 2023
|
PRIMARY | |||
|
NPA5DYB93P
Created by
admin on Sat Dec 16 11:40:48 GMT 2023 , Edited by admin on Sat Dec 16 11:40:48 GMT 2023
|
PRIMARY | |||
|
7141881
Created by
admin on Sat Dec 16 11:40:48 GMT 2023 , Edited by admin on Sat Dec 16 11:40:48 GMT 2023
|
PRIMARY | |||
|
67268-37-5
Created by
admin on Sat Dec 16 11:40:48 GMT 2023 , Edited by admin on Sat Dec 16 11:40:48 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Sepracor; Developer: Sunovion Pharmaceuticals; Class: Analgesic; Mechanism of Action: D amino acid oxidase inhibitor; Highest Development Phases: Discontinued for Alzheimer's disease, Cognition disorders, Neuropathic pain; Most Recent Events: 29 Oct 2010 Discontinued - Phase-I for Neuropathic pain in USA (unspecified route), 29 Oct 2010 Discontinued - Phase-I for Cognition disorders in USA (unspecified route), 29 Oct 2010 Discontinued - Phase-I for Alzheimer's disease in USA (unspecified route)
|
